Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you use bolus in patients s/p mastectomy and reconstruction if they had dermal involvement?
Answer from: Radiation Oncologist at Community Practice
Pathological dermis involvement is a risk factor of LR and I would use bolus for this situation.
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
While we are increasingly omitting bolus, dermal involvement would concern me and I would use bolus.
Comments
Radiation Oncologist at University of Miami/Jackson Memorial Medical Center
Drs. @Sushil Beriwal and @Chirag S. Shah, would yo...
Radiation Oncologist at Allegheny Health Network, Pittsburgh
I typically start with 1st 13 fractions and will m...
Radiation Oncologist at Indiana University Health
@Sushil Beriwal @Chirag S. Shah Would you consider...
9600
9602
15122
Sign in or Register to read more
11755
11772
Related Questions
Given the final publication of NSABP B-51, for which patients meeting trial eligibility would you still recommend regional nodal irradiation?
Given the new ASCO guidelines on SNB in early stage breast cancer, how does the omission of SNB in patients aged 50-70 impact your adjuvant radiation recommendations?
Are you comfortable combining palliative radiotherapy with capivasertib/fulvestrant?
How would you approach an isolated supraclavicular nodal recurrence involving the skin in a patient who has received standard chest wall and nodal radiation therapy?
If a patient has multiple PET-avid level 3, supraclavicular, or IMN nodes that are small and would have been considered negative by size criteria with traditional imaging, that are no longer positive on PET after chemotherapy, would you try to boost these nodes?
What is your approach to women with breast cancer who opts for a staged approach with up-front lumpectomy and SLN biopsy (pN-) when there are indications for adjuvant radiation therapy but she plans for a later mastectomy (=>6 months)?
Do you recommend adjuvant RT to patients with non-ATM genetic mutations (e.g. BRCA, NF) who elect to have lumpectomy and are otherwise PRIME II/CALGB candidates for RT omission (i.e. low risk disease characteristics: strongly ER+, <1cm, grade 1-2, no LVI, widely negative margins, and committed to endocrine therapy)?
Would you consider partial breast irradiation in patients who otherwise meet PBI guidelines who have a pathogenic variant of CHEK2 or other moderate penetrance gene?
Would you offer ultrahypofractionated 5-fraction whole breast only for a women with ER-/HER2+/cN+ disease with pCR following neoadjuvant systemic therapy?
How are you clinically incorporating the data presented from RT Charm at ASTRO 2024?